Live Breaking News & Updates on பெக்கி பெக்

Stay updated with breaking news from பெக்கி பெக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Liver Transplants: Trial Reports Benefits for Cold Perfusion


Feb 26, 2021
Biliary complications significantly reduced with hypothermic oxygenated machine perfusion
The waiting list for liver transplants is long and the Americans who die on that list number in the thousands because there are too few donor organs, but machine cold perfusion may ease the supply deficit.
Organs for liver transplant come from living donors and brain-dead donors. Another source is organs harvested from donors after circulatory death (DCD), which currently make up about 25% of transplanted livers. But patients who received DCD grafts are at risk for worse outcome due to ischemia-reperfusion injury, which can result in bile-duct injury and lead to nonanastom0tic biliary strictures. ....

United States , Winfredw Williams , Peggy Peck , Rianne Van Rijn , Jamesf Markmann , University Of Groningen , Department Of Surgery , Hepatobiliary Surgery , Liver Transplantation , New England Journal , Massachusetts General Hospital , Preventing Nonanastomotic Biliary Strictures , Assessing Donor Livers , Protocol Chair , Transmedics Protect Liver , ஒன்றுபட்டது மாநிலங்களில் , பெக்கி பெக் , பல்கலைக்கழகம் ஆஃப் க்ராநிகந் , துறை ஆஃப் அறுவை சிகிச்சை , ஹெபடோபிலியரி அறுவை சிகிச்சை , கல்லீரல் மாற்று அறுவை சிகிச்சை , புதியது இங்கிலாந்து இதழ் , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , ப்ரோடொகால் நாற்காலி ,

What Drives the Clinical Benefits Seen with SGLT2 Inhibitors?


Feb 5, 2021
Volume, volume, volume may be the answer
As findings from trial after trial provide evidence of the clinical benefit of SGLT2 inhibition in patients with reduced ejection fraction heart failure (HFrEF) DAPA-HF, EMPIRE-HF, EMPEROR-Reduced, there is little convincing left to do about the value of adding SGLT2 inhibitors to the HF armamentarium, as demonstrated by their inclusion in an updated expert decision pathway issued by the American College of Cardiology in early January 2021.
But exactly why these drugs provide these demonstrable benefits is still debatable.
Jesper Jensen, MD, PhD, of Herlev and Gentofte University Hospital, Herlev, Denmark, and University of Copenhagen, Copenhagen, Denmark, and colleagues drilled down into data from a prespecified substudy of EMPIRE-HF (EMPIRE-HF Renal) to investigate the “effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate (GFR) in pat ....

Noord Holland , Hiddojl Heerspink , Peggy Peck , Jesper Jensen , Tanabe Pharma , Eli Lilly , Marcel Ha Muskiet , Mercksharp Dohme , University Of Copenhagen , Amsterdam University Medical Centers , American College Of Cardiology , Boehringer Ingelheim , University Medical Center Groningen , Gentofte University Hospital Herlev , Eli Lilly Alliance , Gentofte University Hospital , Research Council At Herlev , Innovation Foundation Of The Department Cardiology , Novo Nordisk , American College , Lancet Diabetes , Research Council , Innovation Foundation , Medical Science , Mitsubishi Tanabe Pharma , நூற்த் ஹாலண்ட் ,

Drilling Down into DAPA-CKD Findings Confirms Dapagliflozin Benefit


Jan 12, 2021
Consistent benefit regardless of CKD etiology
Once, in the not-too-distant past, one could not scan the latest issue of any top-tier medical journal without finding at least one trial extolling the benefits of statin therapy, which lead many to suggest and not always facetiously that it was time to add statins to the water.
Since late summer 2019 when the results of DAPA-HF were reported at the 2019 European Society of Cardiology Congress in Paris, SGLT2 inhibitors have displaced statins as the pharmaceutical of choice for those who like the “one-drug-fits-all-conditions” approach to the art of medicine.
The latest entry comes from David C. Wheeler, MB, ChB, MD of the George Institute for Global Health in Sydney, Australia, who with his co-investigators offers another look at the findings from DAPA-CKD in ....

France General , United States , New South Wales , Davidc Wheeler , Vifor Fresenius , Peggy Peck , Katheriner Tuttle , Heart Failure Society Of America , European Society Of Cardiology Congress , American Heart Association , Providence Medical Research Center , Providence Health Care In Spokane , Boehringer Ingelheim , George Institute For Global Health , University Of Washington , Cardiology Congress , George Institute , Global Health , Lancet Diabetes , Heart Failure Society , New England Journal , Providence Health Care , Merck Sharp , பிரான்ஸ் ஜநரல் , ஒன்றுபட்டது மாநிலங்களில் , புதியது தெற்கு வேல்ஸ் ,

ACC: VOYAGER-PAD Makes Case for Rivaroxaban | Physician's Weekly


Jan 1, 2021
But if rivaroxaban is ’in’, is DAPT ’out’?
The introduction of direct oral anticoagulants (DOACs) in 2010 significantly changed clinical algorithms for prevention of VTE and stroke, as well as management of atrial fibrillation. In this report, which was initially published March 29, 2020, researchers presented findings that support a role for rivaroxaban in revascularization procedures in patients with PAD. BreakingMED is republishing this report as part of its year end clinical review series.
Findings from a trial of more than 6,564 patients undergoing revascularization procedures for peripheral artery disease are likely to change clinical practice, signaling a death knell for dual antiplatelet therapy while boosting the use of direct oral anticoagulant (DOAC) therapy in these patients. ....

Williamr Hiatt , Marcp Bonaca , Peggy Peck , Sahil Parihk , Roxana Mehran , Board Of Trustees , Vascular Research , University Of Colorado Anschutz Medical Campus , Peripheral Vascular Disease Council , Clinical Research , Community Health , World Congress , Vascular Outcomes Study , Surgical Limb Revascularization , Associate Professor , Colorado Anschutz Medical Campus , Cardiology Virtual , New England Journal , Vascular Disease Council , பெக்கி பெக் , ரோக்ஷணா மெஹ்ரான் , பலகை ஆஃப் அறங்காவலர்கள் , வாஸ்குலர் ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் கொலராடோ அண்சச்சுட்ஸ் மருத்துவ வளாகம் , புற வாஸ்குலர் நோய் சபை , மருத்துவ ஆராய்ச்சி ,